We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health Banks on Health Care Benefit Prospects Amid Woes
Read MoreHide Full Article
On Aug 13, we issued an updated research report on CVS Health (CVS - Free Report) . Increasing demand for Pharmacy Benefit Management (PBM) and specialty pharmacy has been a major driver for the stock. The company currently carries a Zacks Rank #3 (Hold).
Over the past three months, shares of CVS Health have outperformed its industry. The stock has rallied 10.9% compared with 4.2% growth of the industry.
The company delivered promising second-quarter results, demonstrating success in its execution of strategic priorities. Given this agenda, in June, the company announced that it has plans to convert 1500 locations into health hubs by 2021end. In this regard, the company has already started to witness increased customer traffic and incremental sales in pharmacy front store and MinuteClinics at the initial hubs.
In terms of segmental performances, year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in specialty services. We are also pleased with CVS Health’s remarkable progress in the 2020 selling season.
The company’s recently introduced Health Care Benefits segment following the Aetna acquisition is showing a robust momentum, particularly in government business. Notably, CVS Health expects to earn $750 million from near-term synergies of the Aetna integration with low to mid-single digit accretion in the second year post the transaction’s closure.
On the flip side, CVS Health expects 2019 to be transitional as it consolidates Aetna and anticipates its following challenges to leave a certain adverse impact on the operating income of its Pharmacy Services and Retail/LTC segments this year compared with 2018.
Medtronic’s long-term earnings growth rate is expected at 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
NuVasive’s long-term earnings growth rate is expected to be 12.75%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
CVS Health Banks on Health Care Benefit Prospects Amid Woes
On Aug 13, we issued an updated research report on CVS Health (CVS - Free Report) . Increasing demand for Pharmacy Benefit Management (PBM) and specialty pharmacy has been a major driver for the stock. The company currently carries a Zacks Rank #3 (Hold).
Over the past three months, shares of CVS Health have outperformed its industry. The stock has rallied 10.9% compared with 4.2% growth of the industry.
The company delivered promising second-quarter results, demonstrating success in its execution of strategic priorities. Given this agenda, in June, the company announced that it has plans to convert 1500 locations into health hubs by 2021end. In this regard, the company has already started to witness increased customer traffic and incremental sales in pharmacy front store and MinuteClinics at the initial hubs.
CVS Health Corporation Price
CVS Health Corporation price | CVS Health Corporation Quote
In terms of segmental performances, year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in specialty services. We are also pleased with CVS Health’s remarkable progress in the 2020 selling season.
The company’s recently introduced Health Care Benefits segment following the Aetna acquisition is showing a robust momentum, particularly in government business. Notably, CVS Health expects to earn $750 million from near-term synergies of the Aetna integration with low to mid-single digit accretion in the second year post the transaction’s closure.
On the flip side, CVS Health expects 2019 to be transitional as it consolidates Aetna and anticipates its following challenges to leave a certain adverse impact on the operating income of its Pharmacy Services and Retail/LTC segments this year compared with 2018.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Medtronic (MDT - Free Report) , Baxter (BAX - Free Report) and NuVasive Corporation , each presently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is expected at 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
NuVasive’s long-term earnings growth rate is expected to be 12.75%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>